- [Resource Hub](/)
- [Resource](/?resource-type=poster#library)
- Real-time monitoring of CTC number, biomarker expression, and kinetics as prognostic and predictive markers in patients with GI malignancies

# Real-time monitoring of CTC number, biomarker expression, and kinetics as prognostic and predictive markers in patients with GI malignancies

Serial ctDNA testing is slow and costly; this AACR 2024 poster tracked CTC number, biomarker expression and kinetics across 44 patients with advanced or metastatic GI cancers to test CTC analysis as a complementary metric or an alternative to ctDNA.

Presented by RareCyte.

Read or download to see:

- CTCs were detected in 93% of patients and 86% of samples, with an average turnaround of 5-7 days. Across a cohort of 44 patients with advanced or metastatic GI cancers, CTCs were found in 41 of 44 patients and in 67 of 78 blood samples collected, and average CTC testing turnaround time was 5-7 days.

- Colorectal carcinoma carried the highest baseline average count — and by far the widest spread. It was the largest subtype at 30 of the 44 patients, averaging 72 CTCs per 7.5 mL of blood at the initial baseline draw, yet its median was just 3 and individual counts ran from 0 to 1378; the seven other GI subtypes each averaged 9 CTCs or fewer.

- Changes in CTCs tracked treatment response — and in one patient, moved ahead of cfDNA. Rapid decline or clearance occurred within days of effective systemic therapy starting; in Patient 11, CTC number and Ki67 positivity indicated early response prior to cfDNA mutational burden analysis, which read 23% at baseline, 1.9% at week 9 and 0.5% at week 13. Biomarker status was quantified on the CTCs themselves using dual assays — Ki67/EGFR or PD-L1/HER2.

[Download poster](https://cdn.sanity.io/files/s3p6uqps/production/bf293dca89c166ae45c117d42bec62d06749f553.pdf)

Your browser doesn’t support embedded PDFs.
[Download the poster](https://cdn.sanity.io/files/s3p6uqps/production/bf293dca89c166ae45c117d42bec62d06749f553.pdf) to view it.

[Back to all resources](/#library)
## Related resources
[Video](https://www.youtube.com/watch?v=_oGC1KRVN2U) CyteFinder 2026
### Dr. Pashtoon Kasi on the impact of circulating tumor cells on clinical research
[Watch Video](https://www.youtube.com/watch?v=_oGC1KRVN2U) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/43fb6d4a8510166e936d250b3bf172e2f669bfa3.pdf) CyteFinder 2025
### Quantitative analysis of HER2, HER3, and γH2AX expression on circulating tumor cells for pharmacodynamic measurement in clinical trials
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/43fb6d4a8510166e936d250b3bf172e2f669bfa3.pdf) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC10693413/) CyteFinder Frontiers in Oncology 2023
### Circulating tumor cell enumeration, biomarker analyses, and kinetics in patients with colorectal cancer and other GI malignancies
[View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC10693413/) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/e35dfc002f133eaedcf9005374c5ce828f4dc193.pdf) CyteFinder 2022
### Validation of increased sample stability using the AccuCyte®-CyteFinder® CTC Platform to improve logistics in global clinical trials
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/e35dfc002f133eaedcf9005374c5ce828f4dc193.pdf) [Publication](https://doi.org/10.1200/JCO.2026.44.16_suppl.5041) CyteFinder Journal of Clinical Oncology 2026
### Clinical validation of circulating tumor cell synaptophysin and androgen receptor expression in metastatic prostate cancer phenotypes.
[View Publication](https://doi.org/10.1200/JCO.2026.44.16_suppl.5041) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/691cd6e9b37a23fdd7d358244e8fcbac9fc2738b.pdf) 2026
### Clinical Validation of Circulating Tumor Cell Synaptophysin and Androgen Receptor Expression in Metastatic Prostate Cancer Phenotypes
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/691cd6e9b37a23fdd7d358244e8fcbac9fc2738b.pdf) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12881594/) CyteFinder Nature Communications 2026
### Extracellular matrix mediates circulating tumor cell clustering in triple-negative breast cancer metastasis
[View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12881594/) [Publication](https://doi.org/10.1016/j.ejso.2025.111357) CyteFinder European Journal of Surgical Oncology 2026
### Circulating tumor cells predict relapse in head and neck mucosal squamous cell carcinoma
[View Publication](https://doi.org/10.1016/j.ejso.2025.111357) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12805936/) CyteFinder Cancer Research Communications 2026
### Surface Marker Identification to Capture Live Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer
[View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12805936/) [Publication](https://doi.org/10.3390/cancers17162717) CyteFinder Cancers 2025
### Comprehensive Longitudinal Linear Mixed Modelling of CTCs Illuminates the Role of Trop2, EpCAM, and CD45 in CTC Clustering and Metastasis
[View Publication](https://doi.org/10.3390/cancers17162717) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12213210/) CyteFinder Clinical Cancer Research 2025
### Quantitative Protein Expression of Antibody-Drug Conjugate Targets in EGFR Mutated and Wild-Type Non-Small Cell Lung Cancer
[View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12213210/) [Publication](https://doi.org/10.1080/07366205.2025.2534299) CyteFinder BioTechniques 2025
### A novel device for buffy coat collection
[View Publication](https://doi.org/10.1080/07366205.2025.2534299)